VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 476.00K | 605.00K | 501.00K | 493.00K | 486.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 476.00K | 605.00K | 501.00K | 493.00K | 486.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 476.00K | 605.00K | 501.00K | 493.00K | 486.00K |
| SG&A Expenses | 12.14M | 12.70M | 13.19M | 13.91M | 13.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.08M | 46.06M | 44.14M | 38.19M | 31.33M |
| Operating Income | -42.60M | -45.45M | -43.64M | -37.70M | -30.84M |
| Income Before Tax | -38.52M | -42.17M | -39.80M | -33.95M | -27.86M |
| Income Tax Expenses | 4.00K | 4.00K | 4.00K | -- | -- |
| Earnings from Continuing Operations | -38.52 | -42.17 | -39.81 | -33.95 | -27.86 |
| Earnings from Discontinued Operations | -24.00K | -27.00K | -27.00K | -55.00K | -568.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.55M | -42.20M | -39.83M | -34.00M | -28.43M |
| EBIT | -42.60M | -45.45M | -43.64M | -37.70M | -30.84M |
| EBITDA | -29.50M | -21.96M | -12.77M | -6.81M | -13.03M |
| EPS Basic | -0.90 | -0.99 | -0.94 | -0.86 | -2.58 |
| Normalized Basic EPS | -0.58 | -0.62 | -0.58 | -0.53 | -1.51 |
| EPS Diluted | -0.90 | -0.99 | -0.94 | -0.86 | -2.58 |
| Normalized Diluted EPS | -0.58 | -0.62 | -0.58 | -0.53 | -1.51 |
| Average Basic Shares Outstanding | 170.62M | 170.44M | 170.35M | 159.03M | 119.73M |
| Average Diluted Shares Outstanding | 170.62M | 170.44M | 170.35M | 159.03M | 119.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |